Katie Maass is a Senior Principal Scientist, Clinical Pharmacology at Genentech.
She works on the clinical development of new medicines, especially focused on understanding the pharmacokinetics/ pharmacodynamics of drugs to guide the selection of dose and treatment frequency. As a Hertz Fellow, Katie received her PhD in chemical engineering at MIT, where she conducted research in Dane Wittrup’s lab at the Koch Institute for Integrative Cancer Research. Her graduate research focused on the cellular level processing of antibody-drug conjugates, as a targeted cancer therapy. Katie developed a quantitative model of antibody-drug conjugates processing in order to understand what are the rate limiting steps for drug delivery via an antibody-drug conjugate. Katie completed her undergraduate studies in chemical engineering at the University of Texas at Austin. During her undergraduate summers, Katie interned at Merck & Co., MIT’s Center for Material Science & Engineering, and Sachem, Inc., a small chemicals company in Austin, Texas.
